314 related articles for article (PubMed ID: 18307054)
21. Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease.
Chen JJ; Ly AV
Am J Health Syst Pharm; 2006 May; 63(10):915-28. PubMed ID: 16675649
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C; Schumacher HC; Burgut FT
Expert Rev Neurother; 2005 Nov; 5(6):811-21. PubMed ID: 16274338
[TBL] [Abstract][Full Text] [Related]
23. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.
deMarcaida JA; Schwid SR; White WB; Blindauer K; Fahn S; Kieburtz K; Stern M; Shoulson I; ;
Mov Disord; 2006 Oct; 21(10):1716-21. PubMed ID: 16856145
[TBL] [Abstract][Full Text] [Related]
24. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
Smith KM; Eyal E; Weintraub D;
JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
[TBL] [Abstract][Full Text] [Related]
25. Drug selection and timing of initiation of treatment in early Parkinson's disease.
Schapira AH; Olanow CW
Ann Neurol; 2008 Dec; 64 Suppl 2():S47-55. PubMed ID: 19127579
[TBL] [Abstract][Full Text] [Related]
26. Neuroprotective effect of rasagiline in a rodent model of Parkinson's disease.
Blandini F; Armentero MT; Fancellu R; Blaugrund E; Nappi G
Exp Neurol; 2004 Jun; 187(2):455-9. PubMed ID: 15144871
[TBL] [Abstract][Full Text] [Related]
27. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
Tolosa E; Stern MB
Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
[TBL] [Abstract][Full Text] [Related]
28. Monoamine oxidase-B inhibition in the treatment of Parkinson's disease.
Fernandez HH; Chen JJ
Pharmacotherapy; 2007 Dec; 27(12 Pt 2):174S-185S. PubMed ID: 18041937
[TBL] [Abstract][Full Text] [Related]
29. [Rasagiline: effectiveness and protection in Parkinson's disease].
Pagonabarraga J; Kulisevsky J
Rev Neurol; 2010 Nov; 51(9):535-41. PubMed ID: 20979033
[TBL] [Abstract][Full Text] [Related]
30. Rasagiline -- is there a place for this drug in managing Parkinson's disease?
Sharma JC
Int J Clin Pract; 2006 Feb; 60(2):132-3. PubMed ID: 16451281
[No Abstract] [Full Text] [Related]
31. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics.
Olanow CW; Hauser RA; Jankovic J; Langston W; Lang A; Poewe W; Tolosa E; Stocchi F; Melamed E; Eyal E; Rascol O
Mov Disord; 2008 Nov; 23(15):2194-201. PubMed ID: 18932271
[TBL] [Abstract][Full Text] [Related]
32. Rasagiline for the treatment of Parkinson's disease: an update.
Stocchi F; Fossati C; Torti M
Expert Opin Pharmacother; 2015; 16(14):2231-41. PubMed ID: 26364897
[TBL] [Abstract][Full Text] [Related]
33. Rasagiline treatment effects on parkinsonian tremor.
Lew MF
Int J Neurosci; 2013 Dec; 123(12):859-65. PubMed ID: 23767986
[TBL] [Abstract][Full Text] [Related]
34. The role of rasagiline in the treatment of Parkinson's disease.
Leegwater-Kim J; Bortan E
Clin Interv Aging; 2010 May; 5():149-56. PubMed ID: 20517484
[TBL] [Abstract][Full Text] [Related]
35. Rasagiline induced hypersexuality in Parkinson's disease.
Reyes D; Kurako K; Galvez-Jimenez N
J Clin Neurosci; 2014 Mar; 21(3):507-8. PubMed ID: 24055209
[TBL] [Abstract][Full Text] [Related]
36. Rasagiline: a review of its use in the management of Parkinson's disease.
Oldfield V; Keating GM; Perry CM
Drugs; 2007; 67(12):1725-47. PubMed ID: 17683172
[TBL] [Abstract][Full Text] [Related]
37. Determining the efficacy of rasagiline in reducing bradykinesia among Parkinson's disease patients: a review.
Silver DE; Buck PO
Int J Neurosci; 2011 Sep; 121(9):485-9. PubMed ID: 21671840
[TBL] [Abstract][Full Text] [Related]
38. Rasagiline in Parkinson's disease: a review based on meta-analysis of clinical data.
Mínguez-Mínguez S; Solís-García Del Pozo J; Jordán J
Pharmacol Res; 2013 Aug; 74():78-86. PubMed ID: 23735235
[TBL] [Abstract][Full Text] [Related]
39. Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease.
Weinreb O; Amit T; Riederer P; Youdim MB; Mandel SA
Int Rev Neurobiol; 2011; 100():127-49. PubMed ID: 21971006
[TBL] [Abstract][Full Text] [Related]
40. Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson's disease.
Hauser RA; Silver D; Choudhry A; Eyal E; Isaacson S;
Mov Disord; 2014 Jul; 29(8):1028-34. PubMed ID: 24919813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
